NDATRANSDERMALSYSTEM
Approved
Oct 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
CATAPRES-TTS-1 (clonidine transdermal system) by Lavipharm is adrenergic alpha2-agonists [moa]. Approved for central alpha-2 adrenergic agonist [epc]. First approved in 1984.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CATAPRES-TTS-1 is a transdermal clonidine system, a central alpha-2 adrenergic agonist indicated for hypertension management. It delivers medication through the skin over an extended period, providing sustained blood pressure control. The drug works by stimulating alpha-2 adrenergic receptors in the brainstem to reduce sympathetic outflow and lower blood pressure.
LOE Approaching
With LOE approaching and minimal current linked job openings, commercial teams face significant downsizing and resource reallocation toward generic transition management.
Mechanism of Action
Adrenergic alpha2-Agonists
Pharmacologic Class:
Central alpha-2 Adrenergic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CATAPRES-TTS-1 offers limited career growth due to its LOE-approaching status and zero linked job openings; roles focus on managing transition to generics rather than driving innovation or commercial expansion. Career advancement is best pursued by transitioning to growth-stage products within the Lavipharm portfolio or the broader antihypertensive market.
Generic Transition Manager
Worked on CATAPRES-TTS-1 at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.